A circulating miRNA assay as a first-line test for prostate cancer screening.

ABSTRACT:

Background

Prostate cancer (PCa) screening currently relies on prostate-specific antigen (PSA) testing and digital rectal examination. However, recent large-scale studies have questioned the long-term efficacy of these tests, and biomarkers that accurately identify PCa are needed.

Methods

We analysed the levels of circulating microRNAs (miRNAs) in patients with elevated PSA who were diagnosed with either localised PCa (n=36) or benign prostatic hyperplasia (BPH, n=31) upon biopsy. Real-time RT-PCR with Taqman probes was used to measure plasma levels of miRNAs. To circumvent problems associated with circulating miRNA quantitation, we computed the expression ratios of upregulated and downregulated miRNAs.

Results

The miR-106a/miR-130b and miR-106a/miR-223 ratios were si

SUBMITTER: Sharova E 

PROVIDER: S-EPMC4984473 | biostudies-literature | 2016 Jun

REPOSITORIES: biostudies-literature